Aug 25, 2022
Dr. Anthony Japour is the Chief Executive Officer and President at iTolerance, an early-stage privately-held regenerative medicine company. Currently, if a patient receives a pancreatic islet transplant to treat type 1 diabetes, there is a need for lifelong immune suppression. The technology that iTolerance is...
Aug 25, 2022
Dr. Anthony Japour is the Chief Executive Officer and President at iTolerance, an early-stage privately-held regenerative medicine company. Currently, if a patient receives a pancreatic islet transplant to treat type 1 diabetes, there is a need for lifelong immune suppression. The technology that iTolerance is...
Apr 25, 2022
Dr. John Bellettiere is the assistant professor of epidemiology at the Herbert Wertheim School of Public Health and Human Longevity Science at UC San Diego. Alexis Garduno is a third-year student in the UC San Diego and San Diego State University joint doctoral program in public health and the first author in a...
Apr 25, 2022
Dr. John Bellettiere is the assistant professor of epidemiology at the Herbert Wertheim School of Public Health and Human Longevity Science at UC San Diego. Alexis Garduno is a third-year student in the UC San Diego and San Diego State University joint doctoral program in public health and the first author in a...
Mar 22, 2022
Dr. Brian Roberts is a Senior VP and Head of Clinical Development at Rezolute which is developing first in class therapies in the treatment of metabolic diseases. In addition to working on a therapeutic for congenital hyperinsulinism, a rare disease, Rezolute is also in clinical trials with RZ402, an oral small molecule...